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Abstract
Background: The alpha-7 nicotinic acetylcholine receptor (a7-nAChR) is well known as a potent calcium ionophore that, in
the brain, has been implicated in excitotoxicity and hence in the underlying mechanisms of neurodegenerative disorders
such as Alzheimer’s disease. Previous research implied that the activity of this receptor may be modified by exposure to a
peptide fragment derived from the C-terminal region of the enzyme acetylcholinesterase. This investigation was undertaken
to determine if the functional changes observed could be attributed to peptide binding interaction with the a7-nAChR, or
peptide modulation of receptor expression.
Methodology/Principal Findings: This study provides evidence that two peptides derived from the C-terminus of
acetylcholinesterase, not only selectively displace specific bungarotoxin binding at the a7-nAChR, but also alter receptor
binding properties for its familiar ligands, including the alternative endogenous agonist choline. Of more long-term
significance, these peptides also induce upregulation of a7-nAChR mRNA and protein expression, as well as enhancing
receptor trafficking to the plasma membrane.
Conclusions/Significance: The results reported here demonstrate a hitherto unknown relationship between the a7-nAChR
and the non-enzymatic functions of acetylcholinesterase, mediated independently by its C-terminal domain. Such an
interaction may prove valuable as a pharmacological tool, prompting new approaches for understanding, and combating,
the process of neurodegeneration.
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Introduction
Excitotoxicity, due to excessive and deleterious calcium influx
into cells, has long been recognised as a common mechanism
underlying the range of neurodegenerative diseases including
Alzheimer’s, Parkinson’s and Motor Neuron diseases [1–4]. One
of the most powerful calcium ionophores in the brain is the alpha-
7 nicotinic acetylcholine receptor (a7-nAChR; CHRNA7) [5].
Due to its highly selective calcium ion (Ca
2+) permeability, the a7-
nAChR not only facilitates transmitter release via activation of
inhibitory or excitatory Ca
2+-sensitive ion channels, but also
triggers calcium signalling cascades that can initiate gene
transcription, influence axonal pathfinding, and mediate apoptotic
cell death [6–9].
The a7-nAChR receptor has already been implicated directly in
Alzheimer’s disease, in that it binds amyloid-beta (Ab) peptide
[10]. In addition, a7-nAChR expression levels are altered in
relevant mouse models of Alzheimer’s disease [11–13], as well as
in various tissues from human patients [14–16]. Furthermore, the
most effective therapeutic agents for Alzheimer’s disease, such as
the anti-acetylcholinesterase drug galantamine, also target the a7-
nAChR [17–18]. However unlike its other cholinergic counter-
parts, the a7-nAChR can be activated by a primary ligand other
than acetylcholine, ie. choline [19–20]. Hence the a7-nAChR can
function in areas of the brain devoid of cholinergic transmission per
se, where the far more ubiquitous choline may act as a substitute
ligand. This phenomenon is particularly relevant in the light of
reports that Alzheimer’s disease could be linked to an aberration in
choline uptake mechanisms, independent of the cholinergic
synapse [21–23].
Similarly, it has been proposed that acetylcholinesterase (AChE,
EC 3.1.1.7) could have non-enzymatic functions unrelated to the
cholinergic synapse [2,24–26]. Previous evidence, albeit indirect,
has indicated that a 14-amino acid peptide sequence in the C-
terminus of AChE independently modulates a7-nAChR responses
to agonists [27–28]. This peptide bears a striking homology and
structural similarity to Ab [2] and replicates [29–33] many of the
non-hydrolytic actions now well established for the enzyme in a
wide range of preparations and particular situations, such as
development [25–26,34–36] and apoptosis [37–38]. However,
recent detailed analyses of critical amino acid residues [39–40],
potential protease cleavage sites in the C-terminus of AChE [41],
and structural features [39–41], have now identified a larger
candidate bioactive motif of 30 amino acids that encompasses the
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peptides are derived from the ‘‘tailed’’ (T) isoform of AChE and
are comprised of 14 and 30 amino acids respectively, for
convenience they are referred to as ‘T14’ and ‘T30’.
The aim of this study was to compare, in vitro, the direct effects
of T14 and T30 in displacement of radioligand binding of the a7-
nAChR antagonist, a-bungarotoxin (a-BTX), with a number of
scrambled or related peptides serving as controls (Fig. 1).
Moreover, we considered the effects of peptide modulation of
the binding properties of known a7-nAChR ligands, including and
especially, choline. In addition to investigating the effects of the
peptides on receptor binding parameters, we also explored possible
peptide involvement in regulation of the receptor. Accordingly, we
measured the actions of chronic T14 and T30 peptide exposure on
a7-nAChR mRNA and protein expression, as well as subcellular
localization of the receptor.
Results
Peptide-induced changes in a7-nAChR binding
Initial experiments were performed to characterize the binding
parameters of the human a7-nAChR heterologously expressed in
the rat GH4-ha7 cell line using a live-cell binding method.
Saturation binding was carried out with [
125I]alpha-bungarotoxin
([
125I]a-BTX) concentrations ranging from 0.03 nM to 100 nM.
Non-specific binding was determined in the presence of 10 mM
methyllycaconitine (MLA). Total radioligand bound was consis-
tently ,10% of free radioligand in the assay. High levels of
concentration-dependent and saturable specific [
125I]a-BTX
binding in this cell line were observed (Fig. 2A, 2B). The high
correlation coefficient of hyperbolic curve fitting (R
2=0.9775) is
consistent with binding to a single class of receptors. Binding
parameters were established as Bmax=965.8628.9 fmol/mg
protein; Kd=4.6860.61 nM (Mean6SEM). Saturation binding
repeated at intervals throughout the experimental period verified
that the levels observed initially were maintained through multiple
passages (up to 30), demonstrating the stable nature of a7-nAChR
expression by this cell line.
Preliminary screening of the binding of both peptides to the a7-
nAChR, when compared with that of acknowledged receptor
agonists and antagonists, revealed significant, but incomplete,
competition with [
125I]a-BTX for receptor binding sites (Fig. 2C).
T14 exhibited approximately 40% efficacy at 10 mM concentra-
tion, whereas the same concentration of T30 was 70% efficacious.
Higher concentrations of these peptides did not further displace
radioligand binding. In contrast, none of the control peptides were
able to compete with [
125I]a-BTX for binding to the a7-nAChR
(Fig. 2D). Similarly, neither full-length T-AChE, nor truncated
T548, had an effect on [
125I]a-BTX binding to the receptor
(Fig. 2D).
To elucidate further T14 and T30 binding parameters, full
displacement binding profiles were performed (Fig. 2E). Interest-
ingly, a two-phased activity was observed. First, a high affinity
binding was apparent that fit the classic one-site competition
model expected for displacement from a single class of receptors.
T14 and T30 were equally efficacious at the high affinity site,
with maximum displacement at about 45% of total specific
binding, however T30 (Ki=16.861.8 pM) displayed much
greater potency than T14 (Ki=653.3612.6 pM). A second,
lower affinity site was identified for T30 that accounts for a
further 25% binding displacement by the peptide
(Ki=47.162.8 nM). Comparative analysis of the data for T30,
using Akaike’s Information Criteria method, confirmed that the
two-site competition model fits the data better than a one-site
competition model with a .99.99% probability that it is correct.
In contrast, for T14, although a one-site competition model
provided an acceptable fit to the data in the 1 pM to 10 nM
range, with increasing concentrations of peptide .10 nM, a
reversal of displacement efficacy was observed.
We then appraised peptide binding to a7-nAChR in purified
membrane preparations. Unexpectedly, neither T14, nor T30,
had a significant effect on [
125I]a-BTX binding to GH4-ha7 cell
membranes in the 1 pM to 100 nM range (Fig. 3A). As compared
with control maximum specific binding values, a statistically
significant increase in [
125I]a-BTX binding was observed in the
presence of 1 mM (Mean6SEM=110.963.6%, p=0.0271) or
10 mM (117.364.9%, p=0.0172) T30. Conversely, T14 displayed
a small but significant displacement of [
125I]a-BTX binding at
high concentrations (1 mM=90.1163.5%, p=0.0378; 10 mM=
87.9161.9%, p=0.0014).
To explore the possibility that T30 might act through an
allosteric site to affect binding of other a7-nAChR ligands to the
receptor, as has been seen for T14 previously in functional studies,
varying concentrations of T30 were incubated with cell mem-
branes in the presence of methyllycaconitine (MLA), acetylcholine
(ACh), or choline at constant concentrations equivalent to their
measured EC50 values (Fig. 3B). Specific binding displacement
was altered by T30 in a concentration-dependent manner, with
significant decreases in specific binding efficacy of 18% for ACh
(p=0.0426), 24% for MLA (p=0.0032), and 36% for choline
(p=0.0064) as compared with the individual ligands alone.
Subsequently displacement binding was performed for each
ligand in the presence and absence of a constant concentration of
T30 (100 nM). Global fitting analysis was performed to compare
whole binding curve differences. A small but statistically significant
(p=0.032) rightward shift was observed for ACh+T30
(IC50=9.560.5 mM) as compared with ACh alone
(IC50=7.260.3 mM; Fig. 3C). In the presence of T30, the
binding profiles for MLA and choline were similarly shifted to the
right, though to a greater degree than that seen for ACh.
Figure 1. AChE and control polypeptides used in this study. All
isoforms of AChE are derived from a single gene transcript and contain
the invariable exons 2, 3 and 4. The T-AChE isoform arises through
alternative mRNA splicing of exon 6 to the invariable exons. Truncated
AChE (T548) is a recombinant protein, translated from cDNA containing
exons 2, 3, and 4, but lacking a C-terminal exon. The underlined amino
acid sequence highlights the unique C-terminus of the T-AChE isoform
derived from exon 6 of the AChE gene with the location and sequence
of AChE peptides indicated. Control peptides used in experimentation
include: S14, a scrambled version of AChE T14 peptide; B14, comprising
the 14 amino acid region in butyrylcholinesterase (BuChE) that is
homologous to AChE T14; and SB14, the scrambled version of the same
region of BuChE.
doi:10.1371/journal.pone.0004846.g001
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(p=0.006) decrease in competitive potency for MLA+T30
(IC50=15.560.7 nM) as compared with MLA alone
(IC50=9.560.4 nM; Fig. 3D). Since the effect of T30 on choline
binding was greater than that seen for either ACh or MLA, we
expanded the experimental method to examine the effect of a
range of T30 concentrations on choline binding profiles. As shown
in Fig. 3E, we observed a highly significant (p,0.0001)
concentration-dependent decrease in choline competitive potency
in the presence of T30. Comparative IC50 and Ki values are
shown in Table 1. Ki was calculated from the IC50 using the
equation of Cheng and Prusoff [42] based on a constant
radioligand concentration of 2 nM with a Kd=4.68 nM.
We next examined the effects of chronic peptide exposure on
the number of a7-nAChR receptor binding sites and receptor
affinity for [
125I]a-BTX binding (Fig. 4). Cells in culture were
Figure 2. Acute live cell binding in GH4-ha7 cells. Non-specific binding was determined in the presence of 10 mM methyllycaconitine (MLA).
Data shown are the average6SEM of 3 separate experiments. A. Raw saturation binding data shows total, nonspecific, and specific binding for [
125I]a-
BTX to a7-nAChR in this cell line. B. Specific binding of [
125I]a-BTX to a7-nAChR in fmol/mg protein with Scatchard analysis. C. Comparison of maximal
specific [
125I]a-BTX binding displacement by AChE peptides T14 and T30, as compared with known a7-nAChR antagonists and agonists.
ACh=acetylcholine. D. Maximal specific [
125I]a-BTX binding displacement by control peptides, full length T-AChE, and truncated AChE (T548). E.
Displacement binding profiles for AChE C-terminal peptides T14 and T30.
doi:10.1371/journal.pone.0004846.g002
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assays were performed on purified cell membranes using [
125I]a-
BTX in concentrations ranging from 0.033 to 33.0 nM. After
24 hr treatment with T14 or T30, a significant increase
(p=0.0004 and p,0.0001 respectively) in the number of a7-
nAChR binding sites, as determined by maximal binding values,
was observed (Fig. 4). Additionally, the affinity of receptors for
[
125I]a-BTX was significantly decreased (T14, p=0.0035; T30,
p=0.0018) as compared with controls. In contrast to that seen for
T14 and T30 peptides, T15 treatment for 24 hr had no effect on
specific binding affinity of [
125I]a-BTX to the a7-nAChR or on
the number of available receptor binding sites (Fig. 4). Average
Bmax and Kd values for a7-nAChR binding after chronic peptide
exposure are summarized in Table 2.
Figure 3. Acute membrane binding in GH4-ha7 cells. Data shown are the combined results of a minimum of 2 experiments each performed in
triplicate and expressed as percent control specific binding6SEM. A. Competition binding with T14 and T30 concentrations varying from 1 pM to
10 mM. B. Effect of varying concentrations of T30 on a-BTX competition binding with ACh, MLA, and choline. C. Competition binding curve for ACh
vs. ACh+T30 (100 nM). D. Competition binding curve for MLA vs. MLA+T30 (100 nM). E. Competition binding curve for choline vs. choline+T30 at
various concentrations of T30.
doi:10.1371/journal.pone.0004846.g003
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To assess the effects of T-AChE C-terminal peptides on a7-
nAChR mRNA expression, total cellular RNA was isolated and
analysed for gene-specific expression levels using reverse tran-
scriptase PCR. Specifics of primer design and sequences used in
RT-PCR experiments are described in the methods. RT minus
controls were negative and gene expression in control cells did not
change noticeably throughout the series of experiments. Expres-
sion of the housekeeping gene glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) was used as a standard for comparative
analysis. RT-PCR analysis was performed in control GH4-ha7
cells and those exposed to AChE peptides at concentrations
ranging from 1 nM to 1 mM for 24 hr (Fig. 5A). After T14 or T30
peptide treatment, a7-nAChR mRNA expression was significantly
upregulated for all concentrations of the peptides tested as
compared with controls: T14 1 nM 1.7460.08 (relative band
density6SEM), p=0.0225; 10 nM 2.3560.29, p=0.0272;
100 nM 2.7260.22, p=0.0168; 1 mM 1.9660.19, p=0.0411;
T30 1 nM 2.9860.37, p=0.0341; 10 nM 2.9460.14, p=0.0055;
100 nM 2.4960.24, p=0.0263; 1 mM 2.5460.24, p=0.0241.
Levels of a7-nAChR mRNA displayed a concentration-dependent
increase with T14 treatment, with maximal expression at 100 nM.
A similar high level of a7-nAChR expression was achieved after
treatment with only 1 nM T30. As peptide concentrations
increased further, a7-nAChR expression levels remained appre-
ciably enhanced as compared with controls at all peptide
concentrations tested.
To test whether the increased expression observed was directly
attributable to sequence specific T-AChE peptide interaction with
the receptor, rather than random non-specific peptide effects or
structural motif interaction, cells were similarly treated with
control peptides, followed by analysis of a7-nAChR mRNA
expression. No significant change in a7-nAChR mRNA levels was
observed after exposure to T15 (p=0.5893), S14 (p=0.3124), B14
(p=0.4331) or SB14 (p=0.7378) peptides (Fig. 5B). In addition,
neither the full length T-AChE molecule (p=0.3419), nor the
truncated T548 (p=0.1778), effected a significant change in a7-
nAChR mRNA expression.
Table 1. Comparison of EC50 and Ki values showing the
effect of increasing concentrations of T30 on choline binding
to the a7-nAChR.
Ligand IC506SEM (mM) Ki6SEM (mM)
Choline alone 122.967.4 85.965.1
+T30 1 nM 126.0612.8 88.968.9
+T30 10 nM 225.0621.2 157.3616.9
+T30 100 nM 357.4633.0 249.9624.5
+T30 1 mM 736.6668.2 515.1644.6
doi:10.1371/journal.pone.0004846.t001
Figure 4. Specific saturation binding on cell membranes after
chronic treatment of GH4-ha7 cells with 100 nM T-AChE
peptides for 24 hr. Data shown are the average6SEM of 2 separate
experiments each performed in triplicate.
doi:10.1371/journal.pone.0004846.g004
Table 2. Summary of saturation binding parameters showing
the effects of chronic T-AChE peptide treatment on the
number of a7-nAChR binding sites (Bmax) and receptor affinity
(Kd) for a-BTX.
24 hr Treatment Bmax (fmol/mg)6SEM Kd (nM)6SEM
Control 918633.5 4.6660.54
T14 1313650.9 9.0660.93
T30 1704681.1 12.0161.39
T15 949633.0 4.9160.53
doi:10.1371/journal.pone.0004846.t002
Figure 5. RT-PCR analysis of mRNA expression in GH4-ha7 cells
after 24 hr exposure to peptides. GAPDH expression was used as
an internal standard. Gels shown are representative results of
experiments; accompanying graphs provide semi-quantitative data
determined from a minimum of 3 separate experiments. Asterisks (*)
indicate values statistically different from controls. A. Effect of varying
concentrations of AChE peptides T14 and T30 on a7-nAChR expression.
B. Effects of 100 nM control peptides, 10 nM full-length T-AChE, or
10 nM truncated T-AChE on a7-nAChR expression. Lane 1=Control,
2=T15, 3=S14, 4=B14, 5=SB14, 6=full-length T-AChE, 7=truncated
T-AChE (T548). C. Effects of MLA (10 mM) on peptide-induced changes
in a7-nAChR expression in cells treated with 100 nM T14, T30, or T15.
Hash marks (#) indicate peptide+MLA values significantly different
from peptide alone values.
doi:10.1371/journal.pone.0004846.g005
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enhancement using the a7-nAChR specific inhibitor MLA.
Exposure of GH4-ha7c e l l st o1 0mMM L Af o r2 4h ra l s oi n d u c e d
significant upregulation of a7-nAChR expression (1.5860.12,
p=0.0399) as compared with controls, although to a lesser degree
than did 100 nM T14 (2.6160.23, p=0.0269) or T30 (2.7460.19,
p=0.0117) peptides (Fig. 5C). When MLA and T14 (1.5060.12) or
T30(1.5660.09)wereco-appliedhowever,thegreaterenhancement
of peptide-induced a7-nAChR expression was suppressed to levels
observed after MLA treatment alone. Treatment for 24 hr with T15
had no effect on a7-nAChR mRNA expression (p=0.9446) and
T15 co-applied with MLA was non-different from MLA treatment
alone (1.5060.09). Values for T14 or T30 peptide treatments alone
were significantly different than peptide+MLA as determined by
Tukey’s multiple comparison test (p,0.01 and p,0.001 respective-
ly), whereas T15 vs T15+MLA was not (p.0.05).
Peptide-induced changes in a7-nAChR protein
expression
To examine AChE peptide effects on protein expression, a7-
nAChR protein levels were analyzed by SDS-PAGE and Western
blot. A slight, but discernable, upregulation of a7-nAChR protein
expression was detected after only 6 hr exposure to 100 nM T14
or T30 in both total cell homogenates and purified membrane
fractions (Fig. 6A, filled arrowheads). After 24 hr treatment with
peptides, a profound increase in a7-nAChR protein levels was
observed. This increase was particularly pronounced in the
membrane fractions of cells treated with the AChE peptides for
24 hr. Furthermore, T30 treatment induced a greater increase in
receptor protein levels at 24 hr than did T14.
Todeterminewhethertheinduced increaseina7-nAChR protein
levels in the membrane compartment reflects an upregulation of
receptorproteinat theplasmamembrane,peptide-treated GH4-ha7
cells were exposed to the cross-linking agent BS
3 prior to harvesting
for analysis. As can be seen in Fig. 6B, T14 and T30 both increase
a7-nAChR levels in the membrane compartment. In addition,
higher amounts of high molecular weight aggregated species of the
a7-nAChR were observed for T30 incubated cells as compared with
controls (Fig. 6B, empty arrowheads. In order to verify that BS
3 does
not permeate cell membranes, and thus exclude the possibility that
observations were confounded by cross-linked intracellular a7-
nAChR protein, actin levels were also assessed in BS
3-treated cells.
The immunoreactivity for this intracellular protein was unaffected
by the BS
3 treatment (data not shown). In contrast to that seen for
T14 and T30, treatment of the cells for 24 hours with the control
peptide T15 had no effect on a7-nAChR levels in cell membranes
(Fig. 6C).
In addition, we examined changes in a7-nAChR protein further
using immunofluorescent staining. High levels of a7-nAChR
protein were detected in cellular membranes, but not in
cytoplasmic or perinuclear regions (Fig. 7). Background control
cells incubated with secondary antibodies, but lacking primary
antibodies, did not produce a discernable signal (data not shown).
After treatment for 24 hr with T14 (Fig. 7B) or T30 (Fig. 7C),
enhanced signal intensity was evident in cell membranes as
compared with controls (Fig. 7A), with T30-treated cells showing
the greatest increase. In contrast, T15-treated cells were similar in
appearance to control cells (Fig. 7D).
Discussion
Technical Considerations
In general, heterologous expression of the a7-nAChR in non-
neuronal mammalian cells has proven extremely problematic, at
best producing cell lines with only transient or sporadic functional
expression [43]. However the GH4-ha7 cell line (Merck & Co,
Inc, Rahway, USA) chosen for this study, is a stable transfectant
expressing high levels of the human a7-nAChR (Fig. 2B), as well as
a full complement of native cell surface receptors and ion channels
[44]. GH4 cells, derived from a rat pituitary tumor cell line, are
widely established as a model for investigating mechanisms of
intracellular calcium homeostasis and trophic factor release in
secretory cells [45]. These cells also produce high levels of the
chaperone protein RIC-3 [46], recently discovered to be essential
for efficient folding, assembly, and functional expression of the a7-
nAChR in mammalian cells [47]. Thus this cell line is capable of
sustaining high levels of functional a7-nAChR expression and
provides a good model system for study of ligand interactions with
the a7-nAChR.
Figure 6. Representative western blots of a7-nAChR protein
levels in control (C) and peptide (T14, T30) treated GH4-ha7
cells. All experiments were performed a minimum of 2 times. A.
Protein levels as assessed in total cell homogenate and in membrane
compartments after 6 or 24 hr peptide exposure. The filled and open
arrow heads indicate a7-nAChR and actin at 55 and 42 kDa MW,
respectively. Actin was used as an internal standard. B. After 24 hour
peptide treatment, cells were treated with the membrane-impermeant
cross-linking reagent bis(sulfosuccinimidyl)suberate sodium salt (BS
3).
The filled and open arrow heads indicate a7-nAChR and high molecular
weight aggregated species of the a7-nAChR receptor, respectively. C.
Representative western blot of a7-nAChR protein levels in control and
T15 (control peptide) treated cells.
doi:10.1371/journal.pone.0004846.g006
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from T-AChE
For over a decade, it has been known that transient co-
expression a7-nAChR and AChE are spatially and temporally
correlated during development [48–50], where these molecules
play an integral role in the regulation of neuronal proliferation and
differentiation [34,51], neurite outgrowth [26], and programmed
cell death [52–53]. However, many of the prominent features of
developmental processes are recapitulated in degenerative disease
[2] and are similarly accompanied by changes in AChE and a7-
nAChR expression [54–55]. More than two decades ago, Fossier
and colleagues [56] first envisaged a hypothetical, yet direct, non-
hydrolytic action of AChE causing upregulation of the AChR. Yet,
although it is recognized that activation of a7-nAChR can up-
regulate AChE expression [55], possible reciprocal regulation of
the receptor by AChE, has never been investigated. This
suggestion can now be explored more vigorously given current
knowledge of the multiple molecular isoforms of AChE.
Over-expression of the major ‘‘tailed’’ isoform of AChE found in
the adult brain (T-AChE) has been associated with neurodeteriora-
tion [57–58], and induction of apoptosis [59]. Furthermore, T-
AChE accumulates in amyloid plaques, where it enhances Ab fibril
formation and exacerbates the neurotoxic effects of Ab [60–62], in
contrast to an alternative isoform, ‘readthrough’ AChE (R-AChE),
which attenuates these characteristics, and displays neuroprotective
effects following stress-induced upregulation [57,61]. Yet these
AChE isoforms have identical catalytic activity [63], differing only in
their alternatively spliced C-termini [64]. Therefore the differences
seen must be attributable to these unique domains of the proteins.
In parallel to the definitive findings established for R-AChE
[61,65], evidence is only now accumulating that the C-terminal
domain of T-AChE may also undergo proteolytic cleavage in vivo
[41,66–69]. This helical domain independently exhibits autono-
mous bioactivity comparable to many of the non-catalytic effects
attributed to the intact T-isoform of AChE [29–
31,33,35,39,61,66,70]. Whilst the peptide fragment T14 retains
some of the highly conserved residues essential to the functionally
important elements of this domain, the longer T30 peptide
contains more of the critical structural features required for
disulfide bond formation and association with proline-rich
domains, necessary for the formation of the many oligomeric
states of AChE [39].Thus while T14 may comprise a minimal
domain for association with the a7-nAChR, T30 exhibits more
robust bioactivity and has potentially greater physiological
relevance than T14.
Binding of AChE peptides to the a7-nAChR
In live cell preparations, both T14 and T30 displaced [
125I]a-
BTX with high affinity in the picomolar to nanomolar range,
Figure 7. Representative photographs of immunofluorescent staining for a7-nAChR in GH4-ha7 cells. A. Control cells. B. Cells
pretreated for 24 hr with 100 nM T14. C. Cells pretreated for 24 hr with 100 nM T30. D. Cells pretreated for 24 hr with 100 nM T15.
doi:10.1371/journal.pone.0004846.g007
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effects of the two peptides diverged at concentrations greater than
10 nM. While T30 appeared to act at a second site to displace
further [
125I]a-BTX binding, increasing concentrations of T14
caused an opposite effect. Since T30 is a much larger molecule
than T14, it may contact additional allosteric sites on the receptor,
or sites that are moved into proximity due to conformational
changes induced by occupation of high affinity sites. Conceivably,
increasing saturation of a7-nAChR subunits by T30 could
promote either homomeric or heteromeric disulfide bond
formation via the cysteine residues at the C-termini of the peptide
molecules. Moreover, preservation of critical aromatic residues in
T30 confers structural stability to the molecule [39], whereas,
under physiological conditions and at high concentrations, T14
undergoes a conformational change that promotes beta sheet,
fibril, and aggregate formation [71].
The dual binding profile observed with T14 reflects results from
our previous functional studies with the peptide showing that low
concentrations of T14 acutely potentiate neurite outgrowth and
agonist activation of the a7-nAChR [27,31]. On the other hand,
high concentrations, or chronic treatment, with the peptide had
opposite effects, blocking receptor activation by agonists [27] and
inducing apoptotic cell death [30]. This dual trophic-toxic action,
initiatedbypeptide-induced calciuminflux,wassensitive toblockade
by a7-nAChR blockers selectively, appeared to target an allosteric
site, and competed with a7-nAChR agents such as ivermectin.
In fact, concentration-dependent bimodal activity characterizes
ligand interactions with the a7-nAChR, where high and low
ligand concentrations appear to act through temporally distinct
mechanisms at numerous allosteric sites. For example, the a7-
nAChR agonists choline and nicotine exhibit dual effects on
receptor mediated activity, both activating receptors directly and
inhibiting transmission through receptor desensitization [72].
Similarly, many of the AChE inhibiting drugs used in the
treatment of Alzheimer’s disease, such as tacrine, physostigmine,
and galantamine, display concentration-dependent, dual modula-
tion of agonist activation of the a7-nAChR [73–74]. Indeed, Ab
also shows a comparable concentration-dependent bimodal action,
whereby picomolar concentrations activate a7-nAChR and
increase its expression [54], whereas nanomolar concentrations
block receptor activity [75–76].
In contrast to the effects seen for T14 and T30, the control
peptides S14, T15, B14 and SB14 had no effect on [
125I]a-BTX
binding to the a7-nAChR, thus demonstrating the specificity of
T14 and T30 peptides at this receptor. Similarly, neither T548,
nor full-length T-AChE displaced [
125I]a-BTX binding. Since T-
548 lacks the domain proposed to interact with a7-nAChR, this
truncated AChE molecule predictably does not exhibit an ability
to bind to the receptor. Although full-length T-AChE does contain
the critical C-terminal sequence, the intact protein may be too
bulky to allow access to receptor binding sites. Alternatively, the
tertiary structure of the full-length AChE may constrain the C-
terminal region into a conformation that occludes residues
necessary for a7-nAChR binding.
In order to reduce the number of confounding physiological
variables associated with live cell cultures, peptide binding was
assessed in purified membrane preparations, but surprisingly, no
comparable displacement of [
125I]a-BTX binding was detected.
The differences observed between live cell and membrane binding
may be due to dynamic mechanisms in live cells, as opposed to the
static conditions that prevail in purified cell membranes,
suggesting that intermediary factors or temporally dependent
cellular processes could be involved in enabling peptide interaction
with the a7-nAChR. In the live cell binding method, the cells were
incubated with peptides in cell growth medium for two hours at
37uC. During that time, many different physiological processes
could affect binding to the a7-nAChR. Extant intracellular pools
of receptors may be mobilized to the cell surface, receptors may be
internalized and degraded, modulating molecules may interact
with receptors, or with other membrane components, or receptors
may undergo conformational or state changes. In contrast, binding
to isolated membranes was performed at 4uC in a buffered salt
solution, independent of cytoplasmic proteins or cellular processes.
In contrast to results obtained with the peptides alone, co-
application of T30 with ACh, MLA, or choline altered binding of
these ligands to the a7-nAChR. This finding is consistent with the
results of earlier functional studies on T14 bioactivity [27–28] and
indicates that T30 similarly exerts its effects acutely through an
allosteric mechanism. However, given the structural properties of
these peptides, we cannot rule out the possibility that they directly
disrupt the lipid-protein interface by insertion into the plasma
membrane, thereby interfering physically with receptor confor-
mation or local membrane integrity.
For all ligands tested, the presence of T30 caused a right-ward
shift in the binding curve. Early work characterizing the binding
properties of the a7-nAChR showed that modification of receptor
thiol groups and cleavage of disulfide bonds, important in the
manifestation of affinity state changes, decreases the binding
affinity of the receptor for agonists by 10-fold, shifting the dose-
response curve to the right [77]. Likewise, T30 may interact with
thiol groups on the a7-nAChR to alter agonist binding to the
receptor. Alternatively, this amphiphilic peptide may bind an
allosteric site at the lipid-protein interface of the receptor, as has
been shown for cholesterol [78] and the neurosteroid promeges-
tone [79]. However, it is likely that T30 modulation of a7-nAChR
activity will prove highly complex and may involve both steric and
allosteric mechanisms, as has been reported for most a7-nAChR
agonists and non-competitive antagonists studied to date [80].
The observation that T30 can alter choline binding to the a7-
nAChR, is of particular interest, since choline can act as the
primary endogenous ligand for the a7-nAChR during develop-
ment of the nervous system [74] and in areas of the mature brain,
where, paradoxically, both AChE and the a7-nAChR are highly
expressed [48–49], but there is little or no acetylcholine [24].
Under pathological conditions, such as stroke, head trauma and
Alzheimer’s disease, neuronal choline, AChE, and a7-nAChR
levels increase significantly [54–55,81]. While choline activation of
the a7-nAChR may be important for maintaining receptor-
mediated Ca
2+ homeostasis throughout the brain [81], dysregu-
lation of choline metabolism could lead to excitotoxic Ca
2+
imbalances and has been implicated in the selective neuronal
vulnerability characterizing Alzheimer’s disease [22–23,82]. The
modulation observed here, of choline binding to the a7-nAChR by
T30, suggests another potential functional justification for the
presence of AChE in tissues devoid of its familiar substrate.
Saturation binding analysis revealed that chronic treatment with
T14 or T30, but not T15, increased the number of available
receptor binding sites and altered receptor affinity for ligands.
These effects are consistent with that reported for chronic
activation by a7-nAChR agonists, such as nicotine, choline,
carbachol, and Ab [83–86]. However, while agonist-induced
upregulation of a7-nAChR is generally accompanied by increased
affinity of receptors for agonists [83,87], chronic peptide exposure
decreased receptor affinity for agonists and antagonists. Thus,
although AChE C-terminal peptides and a7-nAChR agonists
similarly up-regulate functional a7-nAChR expression, these
newly synthesized, or altered, receptors may exhibit highly
different activity states.
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Consistent with results from saturation binding experiments,
T14 and T30 peptides induced a marked increase in a7-nAChR
mRNA expression. This effect was mitigated by co-application of
the a7-nAChR antagonist MLA, indicating that the peptide-
induced upregulation is the result of direct interaction of the
peptides with the receptor. Meanwhile, peptide controls had no
effect on a7-nAChR mRNA levels, further diminishing the
possibility that the observed increase was due to non-specific
peptide effects. In addition neither the full-length T-AChE, nor
truncated T548, had an effect on a7-nAChR expression levels,
suggesting that regulation of a7-nAChR transcriptional responses
is yet another of the increasing number of effects that cannot be
attributed to the catalytic activity of AChE.
The results obtained with T14 and T30 are similar to that
observed generally for activation of the a7-nAChR by agonists
such as nicotine and choline. For example, nicotine stimulates
rapid Ca
2+-dependent gene transcription through cfos induction
[6], CREB phosphorylation, and MAP-kinase activation [8].
Furthermore, microarray analysis has shown that chronic
exposure to nicotine can cause alteration of gene expression in
over 160 genes [9]. Early reports indicated that nicotine-induced
increases in a7-nAChR expression are dependent on newly
synthesized receptors [84], in contrast to more recent evidence
that suggests receptor upregulation by choline and nicotine may
occur at the post-translational level [85–86]. While the mechanism
by which nicotine exerts its effects is still in contention, the data
presented here clearly show that chronic exposure to nanomolar
amounts of T14 or T30 increases a7-nAChR expression at the
mRNA level.
Peptide-induced increase in a7-nAChR protein levels at
the plasma membrane
Since changes in RNA expression are not necessarily reflected
in equivalent alterations in protein levels, we subsequently
analysed AChE peptide effects on protein expression by Western
blot analysis and immunocytochemistry. After chronic exposure,
both T14 and T30 induced an increase in receptor protein levels.
Fractionation of the whole cell homogenates revealed that the
changes in protein levels seen not only reflected a general increase
in a7-nAChR in the cell as a whole, but that they were particularly
associated with enhanced receptor levels in cellular membranes.
Because the purified membrane compartment is, however,
composed of both intracellular organelle and cellular plasma
membranes, localization of enhanced a7-nAChR protein levels to
the membrane fraction does not definitively prove that the
receptors are reaching the cell surface. By applying the non-
membrane permeable crosslinker BS
3, it was possible to
differentiate intracellular membranes from the plasma membrane,
since only externally accessible proteins are crosslinked by BS
3.
Our results demonstrated that the increase in receptor protein
levels induced by chronic peptide treatment was associated
specifically with the plasma membrane, accompanied by a marked
increase in receptor aggregates, thus reflecting an increased
number of receptor subunits cross-linked together, or with
associated membrane proteins [88].
These findings in Western blots were further substantiated by
immunofluorescent staining with a7-nAChR antibodies. After
treatment with T14 or T30, increased signal intensity was
apparent on cell surfaces, and, consistent with all other results,
T30-treatment elicited the greatest response. Hence selective
peptides derived from the C-terminus of AChE are capable of
causing an increased proliferation in the number of a7-nAChR on
the external surface of cells that express this receptor.
The most likely explanation for the observations is that
interaction of these peptides with the a7-nAChR stimulates
receptor auto-upregulation via Ca
2+ signalling cascades. However,
these results do not rule out the possibility that the peptides could
also interact more directly with signalling molecules or transcrip-
tion factors to modulate a7-nAChR expression, possibly through
interaction with proline-rich domains [40]. Certainly a number of
transcription factors contain such motifs [89], most notably those
involved in apoptosis [90]. Interestingly, it has been shown that T-
AChE is translocated to the nucleus upon initiation of apoptosis
[59], whilst a nuclear form of AChE has been identified in
endothelial cells [69]. Given that the presence of AChE in the
nucleus, particularly in non-neuronal cells, precludes its classical
role in neurotransmission, it is reasonable to speculate that this
molecule contributes in some capacity to the regulation of
transcriptional events. In this regard, it is particularly interesting
to note that transgenic mice over-expressing T-AChE present with
significantly increased levels of a7-nAChR mRNA and protein
[91]. The data reported here demonstrate that chronic exposure to
intact T-AChE does not elicit upregulation of a7-nAChR mRNA,
as do the C-terminal peptides independent of the enzyme. This
finding provocatively suggests that cleavage of the C-terminus may
be a prerequisite for T-AChE-induced upregulation of a7-
nAChR.
Conclusions
In any event, these results demonstrate that a 30mer peptide,
and to a lesser extent one of its 14mer derivatives, define a domain
within the C-terminus of AChE that has the capacity for selective
interaction with the a7-nAChR, not only binding to the a7-
nAChR and altering its affinity for endogenous agonists, but also
upregulating expression of the receptor itself. Given that activation
of a7-nAChR reciprocally up-regulates AChE expression, a
potential positive feedback loop may well coordinate the two
molecules. Although there is only indirect evidence as yet that the
C-terminal of T-AChE, or a peptide fragment thereof, exists
naturally as a free peptide in the brain, of immediate relevance is
the potential to use exogenously applied AChE peptides as
modulators of a7-nAChR expression and function. As such, these
peptides could serve as tools providing novel insights into the
dynamics of a receptor seminal to neurodegeneration.
Materials and Methods
All reagents were purchased from Sigma-Aldrich Co. Ltd.,
Poole, UK, unless otherwise noted. Disposables and cell culture
plasticware were from Fisher Scientific, Loughborough, UK. T14,
S14, B14, and SB14 peptides were custom synthesized by
AnaSpec (San Jose, CA., USA) at .90% purity. T15 and T30
peptides were custom synthesized by Genosphere Biotechnologies
(Paris, France) at .95% purity. All peptides were synthesized by
fmoc methodology, purified by HPLC and analysed by mass
spectrometry. Truncated T-AChE (T-548) was a gift from Palmer
Taylor (Dept of Pharmacology, University of California, San
Diego). [
125I]a-bungarotoxin was purchased from GE Healthcare
Bio-Sciences, Amersham, UK.
Cell Culture
GH4-ha7 cells (Merck & Co., Rahway, USA) were maintained
in Dulbecco’s modified Eagle’s medium (DMEM) with 4500 mg/l
glucose and GlutaMAX (Life Technologies Ltd., Paisley, UK)
containing 10% fetal bovine serum, 100 units/ml penicillin,
100 mg/ml streptomycin, 2.5 mg/ml amphotericin B, and the
selective antibiotic, geneticin (G418; 500 mg/ml).
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For live cell binding experiments, cells were seeded into 6-well
plates at a density of 1610
5 cells/well and allowed to recover for
24–48 hours before experimentation. Cells were treated with
indicated peptides or a7-nAChR ligands for 30 min at 37uC in cell
medium containing 1% FBS. Then [
125I]a-bungarotoxin ([
125I]a-
BTX; 150 Ci/mmol) was added and cells were incubated at 37uC
for a further 1.5 hr. Cell layers were washed 36with 2 ml serum-
free DMEM, then 0.5 ml 1 M NaOH was added to each well to
lyse cells. Cell lysates were transferred to 5 ml scintillation fluid
and radioactivity was determined using a Beckman LS6000IC
scintillation counter.
For membrane binding experiments, confluent cells were
scraped off 75 cm
2 culture plates into ice-cold lysis buffer
(20 mM Tris-HCl, pH 7.0, 5 mM ethylenediaminetetraacetic acid
(EDTA), and 16 protease inhibitor cocktail (Roche Diagnostics,
Ltd.,West Sussex, UK). After pelleting by centrifugation for
10 min at 13,000 rpm, cells were resuspended in 7 ml ice-cold
lysis buffer, lysed by Dounce homogenization, and then centri-
fuged at 10006g for 10 min. Supernatant was removed and the
extraction process repeated. The supernatants were combined and
centrifuged at 50,000 rpm (70 Ti rotor) for 30 min (Beckman
Ultracentrifuge). All centrifugations were carried out at 4uC. The
pelleted membranes were resuspended in binding buffer (50 mM
Tris-HCl, 120 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2.5 mM
CaCl2, pH 7.0) and protein concentration determined using the
DC Protein Assay kit (Bio-Rad Laboratories, Ltd., Hemel
Hempstead, UK). Binding assays were assembled on ice in
borosilicate glass test tubes with 50–100 mg membrane protein in
binding buffer in a final volume of 250 ml. Binding reactions were
incubated at 4uC overnight, and then terminated by rapid vacuum
filtration using a Brandel Cell Harvester onto Whatman GF/B
glass fibre filters pre-soaked in 0.4% polyethylenimine. Saturation
binding experiments were performed with [
125I]a-BTX concen-
trations ranging from 0.03–100 nM. Displacement binding
experiments were performed with a constant [
125I]a-BTX
concentration of 2.0 nM. Non-specific binding was determined
with 10 mM MLA.
Data Analysis
Ligand binding data were analyzed using GraphPad Prism 4.03
(GraphPad Software, Inc.) Saturation binding data were fitted by
nonlinear regression with a hyperbolic function for a one-binding
site model. Displacement binding data were fitted by nonlinear
regression for a one-site binding competition model, unless
otherwise noted. RT-PCR band density data was analysed using
Student’s t-test for comparison of individual means with control
values and by one-way ANOVA followed by Tukey’s multiple
comparison test for comparison of test groups and effect of MLA
inhibition effects.
Total RNA Isolation, cDNA Preparation and PCR
Amplification
Primers for RNA analysis were designed using the Primer3
program [92] and analysed for structural anomalies and dimer
formation using NetPrimer software (Premier Biosoft Internation-
al, Palo Alto, USA). Primer specificity was confirmed by
comparison with DNA sequence databases using nucleotide-
nucleotide BLAST (Available at http://www.ncbi.nlm.nih.gov).
Forward and reverse primers for each gene of interest were
designed from separate exon sequences to eliminate possible
artefacts due to potential DNA contamination in RNA preps.
Primers used were as follows: GAPDH (NM_017008) forward:
gaacatcatccctgcatcca, reverse: ccagtgagcttcccgttca; a7-nAChR
(NM_00746) forward: ggaagctttacaaggagctg, reverse: gccatctgg-
gaaacgaaca.
Total RNA was isolated from GH4-ha7 cells using the Sigma
GenElute
TM Mammalian Total RNA kit. RNA was reverse
transcribed into cDNA using SuperScript First-Strand Synthesis
System (Invitrogen, Paisley, UK) as per the manufacturer’s
instructions. 100 ng cDNA was amplified by PCR with 50 pmol
gene-specific primers, 1.5 mM MgCl2, 200 mM dNTPs, and
1.25 U Taq DNA polymerase (Promega, Southampton, UK) in a
50 ml final reaction volume. After an initial denaturation of 95uC
for 2 min, reactions were amplified for 30 cycles: 95uC for 30 s,
55uC for 30 s, 72uC for 1 min, followed by a final extension of
72uC for 10 min. Reaction products were separated by electro-
phoresis on 1.5% agarose TAE gels and visualized by UV
illumination. Images were captured using a Bio-Rad Gel Doc 2000
and QuantityOne software (Bio-Rad, Hempstead, UK).
Lysate Preparation, Cellular Fractionation, Protein
Evaluation, SDS-PAGE and Western Blot Analysis
After exposure to peptides for indicated times, cells were
harvested in 25 mM Tris HCl containing 2 mM EDTA and 16
protease inhibitor cocktail (Roche Diagnostics, Ltd.,West Sussex,
UK) and pelleted at 4uC and 10,0006g for 10 minutes. Cell
lysates were prepared in lysis buffer containing 25 mM Tris HCl
pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.1 mM phenylmethyl-
sulfonyl fluoride, 0.1% Nonidet, and 16 protease inhibitor
cocktail. Cells were vortexed vigorously for 5 minutes placing on
ice intermittently. After separation of nuclei, J of the cell lysate
was kept as total homogenate for further analysis, while the
remaining L was used to separate out the membrane fraction.
Briefly, cell lysates were pelleted by centrifugation for 50 minutes
at 4uC and 100,0006g. The resulting pellets (membranes) were
resuspended in lysis buffer and protein levels (a7-nAChR and
actin) were determined by western blot analysis. Equal amounts of
protein were prepared in Laemmli buffer, separated in 7% SDS-
PAGE and blotted onto nitrocellulose membrane. For immuno-
detection, the following antibodies were used: anti-a7-nAChR
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution
1:200), anti-actin (Sigma-Aldrich, Poole, Dorset, UK; dilution
1:5,000), peroxidase-conjugated donkey anti-goat (Sigma-Aldrich,
Poole, Dorset, UK; dilution 1:10,000), and peroxidase-conjugated
goat anti-rabbit (Pierce, Rockford, IL, USA, dilution 1:10,000).
Blots were developed with enhanced chemiluminescence (ECL;
GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Immunocytochemistry
GH4-ha7 cells were seeded into 12-well cell culture plates
(5610
4 cells/well) containing 13 mm glass coverslips pre-coated
sequentially with poly-D-lysine (MW 30,000–70,000; 1 mg/ml)
and rat tail-derived collagen Type 1A (100 mg/ml). Cells were
allowed to recover for 24–48 hours before experimentation. After
treating cells with peptides (100 nM) for 24 hr, medium was
removed and cells were washed with phosphate-buffered saline
(PBS; 10 mM phosphate buffer, pH=7.4, 150 mM NaCl,
2.7 mM KCl). Cells were fixed with 2% paraformaldehyde in
phosphate buffer (100 mM, pH=7.4), permeablized with 0.1%
Triton X-100 in PBS, blocked with 2% bovine serum albumin
(BSA) in PBS, and then incubated with goat anti-a7-nAChR
(Santa Cruz Biotechnology, Santa Cruz, CA, USA; dilution 1:100)
in 2% BSA/PBS buffer for 1.5 hr. After thorough washing with
PBS to remove excess primary antibody, cells were incubated with
Alexafluor 488-conjugated donkey anti-goat secondary antibody
(1:800; Molecular Probes) overnight at 4uC. Cells were washed
Upregulation of a7 Receptors
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ProLong GoldH anti-fade mounting medium (Life Technologies
Ltd., Paisley, UK). Fluorescent signals were visualized using a
Leitz Diaplan microscope and images were captured with a Leica
DFC300FX digital camera and Leica DFC Twain imaging
software (Leica Microsystems Ltd., Milton Keynes, UK). For
assessment of a7-nAChR protein expression, at least 3 coverslips
were examined for each control and peptide treatment and a
minimum of 12 randomly selected visual fields (406) were
acquired from each coverslip.
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